IGC Pharma, Inc.

As of August 10, 2023, IGC Pharma, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 3.90 and negative EV ratios, despite a strong year-to-date return of 22.59%, which contrasts sharply with its long-term performance of -65.39% over five years.

As of August 10, 2023, IGC Pharma, Inc. is classified as "risky" and overvalued, with concerning financial metrics and a one-year return of -44.47%, significantly underperforming the S&P 500.

As of May 16, 2025, the trend is mildly bearish due to daily moving averages, despite some positive momentum from weekly indicators, with overall cautious sentiment reinforced by underperformance relative to the S&P 500.

As of March 2022, the management team of IGC Pharma, Inc. includes Mr. Richard Prins as the Independent Chairman of the Board and Mr. John Lynch as a Director.

IGC Pharma, Inc. develops phytocannabinoid-based therapies for serious health conditions and operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $23.91 million. As of December 2024, the company reported net sales of $0 million and a net loss of $2 million.

As of Jun 18, IGC Pharma, Inc. has a market capitalization of 23.91 million and reported net sales of 1.23 million with a net profit of -8.81 million over the last four quarters. The company has shareholder's funds of 7.32 million and total assets of 9.90 million as of Mar 24.